What is true regarding the use of rtPA in acute ischemic stroke?

What is true regarding the use of rtPA in acute ischemic stroke?

• A. It is indicated for all stroke patients
• B. Can only be given within 24 hours of symptom onset
• C. It is a thrombolytic agent used to restore blood flow
• D. Requires hospitalization for administration

Answer: (C)

The use of rtPA (recombinant tissue plasminogen activator) in the context of acute ischemic stroke is particularly significant because it serves as a thrombolytic agent, which means its primary role is to dissolve blood clots that obstruct blood flow to the brain. When administered promptly, rtPA can help restore circulation, thereby minimizing brain damage and improving the chances of recovery. Timely administration is crucial; rtPA is most effective when given within a narrow time window following symptom onset, typically within three to four and a half hours. However, it is not indicated for all stroke patients, nor can it be safely administered beyond this timeframe due to the increased risk of hemorrhagic complications. Additionally, administering rtPA generally necessitates that the patient is hospitalized, where they can be closely monitored for potential adverse effects, such as bleeding. This monitoring is a critical aspect of patient safety in acute stroke management. Overall, option C highlights the therapeutic aim of rtPA and its function in the acute management of ischemic stroke, making it the correct choice.

The use of rtPA (recombinant tissue plasminogen activator) in the context of acute ischemic stroke is particularly significant because it serves as a thrombolytic agent, which means its primary role is to dissolve blood clots that obstruct blood flow to the brain. When administered promptly, rtPA can help restore circulation, thereby minimizing brain damage and improving the chances of recovery.

Timely administration is crucial; rtPA is most effective when given within a narrow time window following symptom onset, typically within three to four and a half hours. However, it is not indicated for all stroke patients, nor can it be safely administered beyond this timeframe due to the increased risk of hemorrhagic complications.

Additionally, administering rtPA generally necessitates that the patient is hospitalized, where they can be closely monitored for potential adverse effects, such as bleeding. This monitoring is a critical aspect of patient safety in acute stroke management.

Overall, option C highlights the therapeutic aim of rtPA and its function in the acute management of ischemic stroke, making it the correct choice.